Afobazole Nanoparticles Formulation for Enhanced Therapeutics

Competitive Advantages

  •     Higher blood brain barrier permeability
  •     Controlled, sustained drug release
  •     Enhanced neuroprotection in cases of ischemic (stroke) damage

Summary

USF scientists have addressed this problem with a new formulation of the drug using nanoparticle (NP) technology. Specifically, this novel invention utilizes a NP carrier encapsulating afobazole to effectively improve blood brain barrier permeability, with a coating of glutathione (GSH) that facilitated interaction with the BBB. Drug release studies have shown that this formulation also results in sustained release of the drug to the brain tissue after deployment in vivo. Studies show that this method of delivery for the drug is more effective at protecting neurons from suffering damage following the event of an ischemic stroke. These improved pharmacokinetics may be leveraged to develop treatments that will improve outcomes of patients suffering from various CNS diseases involving excessive neuronal activity and inflammation. 

Absorbance Profile Shows Increased BBB Permeability of  the Novel Nanoparticle Formulations (GSH-Afo NPs) 

Desired Partnerships

  • License
  • Sponsored Research
  • Co-Development
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Afobazole Nanoparticles Formulation for Enhanced Therapeutics Nationalized PCT United States 15/474,463 10,172,867 3/30/2017 1/8/2019 3/30/2037